Correlation Between Acumen Pharmaceuticals and Precision BioSciences

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Acumen Pharmaceuticals and Precision BioSciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acumen Pharmaceuticals and Precision BioSciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Acumen Pharmaceuticals and Precision BioSciences, you can compare the effects of market volatilities on Acumen Pharmaceuticals and Precision BioSciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acumen Pharmaceuticals with a short position of Precision BioSciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acumen Pharmaceuticals and Precision BioSciences.

Diversification Opportunities for Acumen Pharmaceuticals and Precision BioSciences

-0.09
  Correlation Coefficient

Good diversification

The 3 months correlation between Acumen and Precision is -0.09. Overlapping area represents the amount of risk that can be diversified away by holding Acumen Pharmaceuticals and Precision BioSciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Precision BioSciences and Acumen Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acumen Pharmaceuticals are associated (or correlated) with Precision BioSciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Precision BioSciences has no effect on the direction of Acumen Pharmaceuticals i.e., Acumen Pharmaceuticals and Precision BioSciences go up and down completely randomly.

Pair Corralation between Acumen Pharmaceuticals and Precision BioSciences

Given the investment horizon of 90 days Acumen Pharmaceuticals is expected to under-perform the Precision BioSciences. In addition to that, Acumen Pharmaceuticals is 1.21 times more volatile than Precision BioSciences. It trades about -0.15 of its total potential returns per unit of risk. Precision BioSciences is currently generating about -0.12 per unit of volatility. If you would invest  828.00  in Precision BioSciences on August 28, 2024 and sell it today you would lose (104.00) from holding Precision BioSciences or give up 12.56% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Acumen Pharmaceuticals  vs.  Precision BioSciences

 Performance 
       Timeline  
Acumen Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Acumen Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.
Precision BioSciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Precision BioSciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's forward indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Acumen Pharmaceuticals and Precision BioSciences Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Acumen Pharmaceuticals and Precision BioSciences

The main advantage of trading using opposite Acumen Pharmaceuticals and Precision BioSciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acumen Pharmaceuticals position performs unexpectedly, Precision BioSciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Precision BioSciences will offset losses from the drop in Precision BioSciences' long position.
The idea behind Acumen Pharmaceuticals and Precision BioSciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Other Complementary Tools

FinTech Suite
Use AI to screen and filter profitable investment opportunities
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Technical Analysis
Check basic technical indicators and analysis based on most latest market data